Ethicon Decision to Market Prolift Vaginal Unethical, Experts Say
Citing the different correspondences of Ethicon officials and the results of its internal studies, a urogynecology expert asserted that Ethicon, a subsidiary of Johnsons & Johnson, should have never marketed or sold the Prolift vaginal mesh for the treatment of pelvic organ prolapse (POP) and stress urinary incontinence (SUI). The business decision to promote the contraption as a POP and SUI solution may be questionable along ethical grounds, says Dr. Anne Webber during her testimony in the Linda Gross lawsuit against Ethicon.
She called the decision of Ethicon to proceed with their marketing of the Prolift vaginal mesh as unethical. This was how she described the actuations of Ethicon officials for insisting on making the product available to the market even after they were made aware that the Prolift had characteristics that may result to complications which may eventually cause irreparable damage to patients.
This unethical behavior was further manifested in the decision of the company not to include the deficiencies of the product on its label, as mandated by law. To make matters worse, officials tried to mislead the public by projecting Prolift as a safe and effective medical device for the treatment of these pelvic disorders.
Read More: Ethicon Made Unethical Decisions Re: Prolift Mesh Product, Doc Testifies